u/EaseQuiet529

Philip Morris International ($PM): the multi-billion-dollar pivot to a "smoke-free" future is actually working.

🚀 **ZYN & IQOS Are Dominating:** Thanks to the massive explosion of ZYN nicotine pouches and IQOS heat-not-burn tech, alternative products now make up over **40%** of PM’s total net revenues.

🛡️ **A Massive Regulatory Moat:** The FDA’s historic authorization of certain ZYN variants as a "lower-risk alternative to cigarettes" gives them a massive marketing edge that competitors simply don't have.

📈 **Wall Street Re-rating:** PM is moving away from the compressed valuations of legacy tobacco. As it starts looking more like a high-growth consumer packaged goods company, analysts expect the stock's P/E multiple to expand.

💰 **The Dividend Floor:** On top of the growth narrative, $PM still delivers a highly resilient, defensive business model paired with a hefty, reliable dividend yield.

While traditional cigarette volumes decline, Philip Morris has essentially built a high-margin replacement engine.

#Investing #StockMarket #PhilipMorris #ZYN #ValueInvesting #StocksToWatch #Dividends #FinanceNews

Happy Fourth of July!

Wishing you all a fantastic day!

SpaceX (SPCX) is scheduled to officially join the Nasdaq 100 index before the opening bell on July 7, 2026.

Index funds and ETFs that track the benchmark are legally required to purchase billions of dollars worth of the stock. Wall Street firms estimate this passive buying could trigger over $4 billion in immediate inflows, providing strong buying pressure.

If you are a long-term believer in Elon Musk's orbital infrastructure and AI dominance, buying a partial position now captures the Nasdaq 100 inclusion momentum. However, conservative investors may prefer to wait out the extreme post-IPO volatility and see how the stock handles its upcoming share unlock periods later this year.

#SpaceX #SPCX #Nasdaq100 #Investing #IPO #Stocks

The market right now is a massive sector rotation. Investors are taking profits from high-flying, mega-cap tech and AI stocks and plowing that cash into healthcare, biotech, and consumer-sensitive sectors.

The healthcare sector logged a spectacular 7.3% jump—its biggest weekly gain in over four years—driven by massive M&A news and regulatory wins.

Bio-Techne (TECH) | +23%

AbbVie (ABBV) | +17%

​Charles River Laboratories (CRL) | +17%

Incyte (INCY) | +16%

#stock #stockmarket #investment #news

Ross store is a off-price retailer. They don't buy directly from manufacturers ahead of a season; instead, they operate as a giant liquidation pipeline.

**Business model:

Ross utilizes the massive shopping network year-round. When mainstream brands, department stores, or manufacturers experience canceled orders, overproduction, or excess inventory, Ross steps in and buys the merchandise at a steep discount (typically 20% to 60% below standard wholesale cost).

Ross rapidly changes assortments of brand-name products. This creates a psychological "treasure hunt" effect for consumers: shoppers know that if they don't buy an item today, it will likely be gone tomorrow.

Ross's low prices and "treasure hunt" format make it highly insulated from online E-commerce competition.

Ross is capturing massive customer acquisition numbers across multiple demographics, notably younger shoppers.

**Stock ROST:

Ross shattered Wall Street expectations for Q1 2026, driving a major 8% stock pop after posting its strongest performance in years. Total sales hit $6.0 billion, and same-store comparable sales grew significantly higher than projections. Crucially, management raised its full-year 2026 EPS outlook to a robust range of $7.50 to $7.74, giving analysts strong fundamental backup to lift price targets.

Wall Street maintains a Strong Buy / Moderate Buy consensus on the stock.

Average (Consensus) Price Target: $253.00 to $261.00

High-End Estimates: $290.00 to $297.00

#RossStores #ROST #StockMarket #Investing #ValueInvesting #OffPriceRetail #RetailStocks

If you have heavy exposure to high-flying AI tech stocks, balancing your portfolio means adding assets that behave differently when the tech sector pulls back. You need to hedge the AI tech stocks volatility.

The true hedge stocks should have strong momentum and high growth.

​Eli Lilly (LLY): A global pharmaceutical giant.

Massive structural growth. In Q1 2026, worldwide revenue skyrocketed 56% year-over-year to $19.8 billion, driven by explosive global demand for Mounjaro and Zepbound. Lilly raised its full-year 2026 revenue guidance to an unprecedented $82 billion to $85 billion. Its momentum is intensely bullish.

​Caterpillar (CAT): The world's leading manufacturer of construction.

A massive momentum surprise. Driven by a record $63 billion order backlog for data center power generation engines and electrical turbines, CAT has experienced a historic re-rating. The stock has surged roughly 172% over the last year, trading over $1,000 with Q1 2026 power generation revenue jumping 41% and overall revenue up 22%.

NextEra Energy (NEE): A premier clean energy company.

Strong momentum turnaround. After a quiet period, the reality of massive AI utility grid demand has triggered a revenue spike. Trailing twelve-month revenue grew over 47% due to clean energy project expansions, while Q1 2026 quarterly revenue rose 7.2% year-over-year.

​#Investing #StockMarket #AI #PortfolioManagement #FinanceTips #LLY #CAT #NEE

If you are looking for stocks with momentum as well as those that might offer attractive value, here are the top 10 featuring stocks from Fidelity that are up at least 16.8% year to date, have a positive P/E-to-growth (PEG) ratio of 1.76 and below, and a 90-day daily volume average of at least 317.69K, sorted by market cap, as of June 25, 2026:

Taiwan Semiconductor (TSM)

Micron (MU)

Sandisk (SNDK)

GE Vernova (GEV)

Royal Bank of Canada (RY)

Dell (DELL)

Western Digital (WDC)

Citigroup (C)

Seagate Technology (STX)

Toronto-Dominion Bank (TD)

#stock #stockmarket

Wall Street views Medtronic (MDT) as a temporarily beaten-down industry giant that has finally unlocked its growth gears. The market hasn't priced in this operational shift yet, offering a high-margin opportunity for investors to grab value and growth at a heavy discount.

​

## 1. Striking Financial Turnaround

Medtronic recently reported phenomenal fourth-quarter earnings that fundamentally changed the growth narrative:

​

**Record Growth: Revenue rose 9.9% year-over-year in Q4 to $9.7 billion, driving full-year growth to 8.4%—marking Medtronic's strongest annual top-line performance in 10 years.

​

**Strong Guidance: Management raised future expectations, guiding for organic revenue growth between 6.75% and 7.25% and targeting an 8% increase in adjusted earnings ($5.90 to $6.00 per share).

​

## 2. A Massive "Innovation Cycle" Catalysts

Wall Street analysts note that Medtronic is at the front-end of the most significant innovation cycle in its history, with strong pipelines across major healthcare sectors:

​

**Cardiovascular Leadership: Its Cardiovascular and Ablation Solutions (CAS) business is gaining significant market share. Medtronic holds a massive competitive advantage as the only company with two distinct FDA-approved Pulsed Field Ablation (PFA) platforms (PulseSelect and Affera System) to treat heart tissue with minimal risk to surrounding areas.

​

**Neuroscience & AI: Neuroscience revenue jumped 5% in Q4. Medtronic is capturing a massive slice of the $15 billion cranial and spinal technologies market using its **AiBLE surgical platform**, which merges predictive AI software with specialized hardware. 💫

​

**Robotic-Assisted Surgery (RAS): The company is rapidly expanding its Hugo RAS device. Priced at a roughly 40% discount to Intuitive Surgical's dominant *da Vinci* system, the Hugo platform has already secured U.S. clearance for urology and is expanding into general and gynecologic surgeries, positioning it perfectly for a market projected to hit $54 billion. 💫

​

## 3. Rare "Value + Growth" and Safety Net

Despite these high-tech growth tailwinds, the stock is deeply discounted:

**The Valuation Disconnect: It trades at a cheap 13.5 to 14 times forward earnings, lower than its 10-year historical average of 16. Its Price-to-Sales (P/S) ratio sits at 2.8, a steep bargain compared to its direct peers (Abbott, Boston Scientific, Stryker, and J&J), which command an average P/S of 4.

​

**The Dividend Safe Haven: For defensive investors, Medtronic offers a sturdy 3.7% dividend yield (72 cents per quarter) and is on track to continue its 49 consecutive years of dividend increases.

​

Targeting price $120

​

​

#Stocks #Investing #investment #stockmarket #Medtronic #MarketTurnaround

​

​

​

​If you’ve spent much time reading the strategy discussions on the internet, you know that the biggest enemy to a solid trading plan isn't a bad indicator—it's human emotion.

​ ​It’s easy to write down a plan like "I will buy the dip if this ETF hits its 200-day moving average" or "I will take profit on this crypto asset at a 15% gain." But when the market actually moves, hesitation, greed, and panic take over. You wait too long, miss the window, or sell at the absolute bottom.

​ That's why we need automated execution -- it comes to run multi-asset automation without coding, catch pumps and skip dips for you. Find my favorite trading platform in my profile, and feel free to try it.

​ /#trading #platform #tool #stock #ETF #crypto #bitcoin #market #exchange

Wall Street views General Motors (GM) not just as a traditional car manufacturer, but as a "cash-compounding machine."

​ Despite a turbulent macro environment—including changing EV policies, inflation, and recent tariff pressures—GM has generated roughly $53 billion in free cash flow since 2021. Even with a minor downturn in 2025, it ended the year with a stellar free-cash-flow yield of 14% (compared to the S&P 500 average of around 3%).

​ GM has weaponized its cash by spending roughly $30 billion to retire 500 million shares over the past five years, shrinking its outstanding share count by nearly 35%. Because they are buying back shares at a deep discount to their intrinsic value, they are dramatically boosting per-share earnings power.

​ GM currently trades at a rock-bottom 6.5 times estimated 2026 earnings, while the broader S&P 500 trades at 22 times. Even if Wall Street refuses to grant GM a higher valuation multiple, the shrinking share count alone guarantees double-digit per-share gains.

​ The company's financial position is vastly structurally improved compared to prior cycles; it can break even at much lower sales volumes than before, and it didn't even lose money during the 2020 pandemic lockdown.

​ The more important thing--emerging industrial expansion. GM newly announced defense partnership with Lockheed Martin—provide further upside.

​ If mainstream investors finally give GM credit for its structural stability and strong management, Wall street projects the stock could rise to $135 within a year—representing an approximate 50% gain from its current trading price (~$79–$80).

​ #GM #StockMarket #Investing #investment #strategy #Value #AutoIndustry ​ ​

When the Fed removes forward guidance, the era of buying speculative, unprofitable growth companies on the promise of "future earnings" is over. Higher interest rates punish companies with heavy debt.

​

​The Action: Review your stock portfolio and filter for Quality Factors.

​

​The Strategy: Focus on companies with:

1. ​Strong balance sheets and low debt-to-equity ratios (so they don't have to refinance at Warsh's higher interest rates).

2. ​Positive, robust free cash flow to fund their own growth without borrowing.

3. ​Strong pricing power (the ability to pass higher costs onto consumers, which is vital with CPI stuck at 4.2%).

​

Pivot to Quality: Focus on "bulletproof" companies with massive free cash flow, low debt, and strong pricing power to survive sticky 4.2% inflation.

​

​Embrace Cash & T-Bills: Cash is no longer trash. With rates near 4%, parking sidelined cash in short-term Treasury bills earns you a safe yield while you wait out the market turbulence.

​

​Ditch the Speculation: Rotate away from highly leveraged sectors like real estate (REITs) and unprofitable growth stocks, and look toward sectors that lean into higher rates, like financials.

​

#Investing #Fed #InterestRates #StockMarket #Finance #Inflation #KevinWarsh

​

​